Bartlett & Co’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Bartlett & Co’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-37,037	Closed	-$156K	–	1182
2023 Q1	$156K	Hold	37,037	–	–	﹤0.01%	410
2022 Q4	$223K	Hold	37,037	–	–	﹤0.01%	373
2022 Q3	$216K	Buy	+37,037	New	+$231K	﹤0.01%	365
2022 Q2	–	Sell	-36,500	Closed	-$170K	–	1331
2022 Q1	$170K	Hold	36,500	–	–	﹤0.01%	405
2021 Q4	$91K	Buy	+36,500	New	+$89.3K	﹤0.01%	401

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Bartlett & Co's CTIC Position: Q2 2023 in Review

Bartlett & Co sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 37,037 shares — an estimated $156K sold.

Bartlett & Co first reported a position in CTIC in Q4 2021 and held it in 5 quarters. The position peaked at $223K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Bartlett & Co reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Bartlett & Co sold 37,037 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $156K.
Bartlett & Co first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2021 and held it in 5 quarters.
Bartlett & Co's CTI BioPharma Corp. (DE) Common Stock position peaked at $223K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Bartlett & Co's 13F filing for Q2 2023, filed 14 Jul 2023.